Welcome to Multibagg AI
Log in to access personalized features
IRIS
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Research powered by GOALZEN CAPITAL SERVICES PRIVATE LIMITED · SEBI Research Analyst INH000013448
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stockBearish
4
Neutral
3
Bullish
7
Bearish
25
Neutral
3
Bullish
18
Bearish
21
Neutral
0
Bullish
11
Bearish
4
Neutral
3
Bullish
7
Bearish
4
Neutral
3
Bullish
7
Bearish
21
Neutral
0
Bullish
11
Bearish
21
Neutral
0
Bullish
11
Bearish
21
Neutral
0
Bullish
11
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Kopran Ltd (KOPRAN) is currently trading at 245.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Kopran Limited is an integrated pharmaceutical company operating two verticals—formulations under Kopran Limited and APIs through wholly owned subsidiary Kopran Research Laboratories Ltd—manufacturing finished dosage forms and active pharmaceutical ingredients for regulated and non-regulated global markets with approvals from multiple international regulators and exports to over fifty countries. The company reported consolidated Q1 FY2026-27 revenue of Rs.15,399 lakhs and EBITDA of Rs.1,588 lakhs, with EBITDA margin compressing to 10.31% from 17.38% in Q4; Q1 showed a positive forex gain versus prior quarter losses, but sequential revenue and profitability volatility highlight sensitivity to seasonality, forex and product mix. Operational strengths include leadership in Atenolol and sterile carbapenems, a portfolio of 26 commercialised APIs and over 100 formulation dosages, multiple GMP accreditations (MHRA, Health Canada and others) and a strategy focused on R&D, backward integration and regulatory filings to expand niche, higher-value API offerings and global registrations. Strategic priorities emphasised in the presentation are cost leadership, de-risking China dependence, process improvements and automation, and capacity expansion at Panoli and Mahad; at the same time borrowings and fixed assets have risen, implying active capex deployment and ongoing balance between investment and margin recovery efforts.
Over the past 52 weeks, Kopran Ltd has traded between a low of ₹107.00 and a high of ₹295.90. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Kopran Ltd has a market capitalization of approximately 1,193.90. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Kopran Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 47.78 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 1,193.90 Cr, Kopran Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Kopran Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Kopran Ltd is 47.78. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Consolidated revenue from operations was ₹153.99 crore and consolidated PAT was ₹6.70 crore for the quarter ended June 30, 2026.
Discovery themes featuring this stock
Kopran Limited is an integrated pharmaceutical company operating two verticals—formulations under Kopran Limited and APIs through wholly owned subsidiary Kopran Research Laboratories Ltd—manufacturing finished dosage forms and active pharmaceutical ingredients for regulated and non-regulated global markets with approvals from multiple international regulators and exports to over fifty countries.
The company reported consolidated Q1 FY2026-27 revenue of Rs.15,399 lakhs and EBITDA of Rs.1,588 lakhs, with EBITDA margin compressing to 10.31% from 17.38% in Q4; Q1 showed a positive forex gain versus prior quarter losses, but sequential revenue and profitability volatility highlight sensitivity to seasonality, forex and product mix.
Operational strengths include leadership in Atenolol and sterile carbapenems, a portfolio of 26 commercialised APIs and over 100 formulation dosages, multiple GMP accreditations (MHRA, Health Canada and others) and a strategy focused on R&D, backward integration and regulatory filings to expand niche, higher-value API offerings and global registrations.
Strategic priorities emphasised in the presentation are cost leadership, de-risking China dependence, process improvements and automation, and capacity expansion at Panoli and Mahad; at the same time borrowings and fixed assets have risen, implying active capex deployment and ongoing balance between investment and margin recovery efforts.
Pharmaceuticals & Biotechnology
Pharmaceuticals
1,194 Cr
High Risk
47.8
34.8
-1.7
2.3
295.90
107.00
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
454.90 | 1,339 Cr | 23.01 | 3.29 | 0.80 | 17.67 | 20.02 | 8.98 | ||
247.05 | 1,194 Cr | 47.78 | 2.25 | 1.21 | 4.85 | 6.56 | 2.75 | ||
1662.75 | 1,146 Cr | -38.21 | 3.56 | 0.06 | -2.54 | -1.83 | -4.89 | ||
449.85 | 1,064 Cr | 136.61 | 11.07 | 0.00 | 11.54 | 10.63 | 4.44 | ||
312.65 | 1,052 Cr | 42.17 | 1.89 | 0.48 | 10.45 | 10.75 | 2.10 | ||
880.60 | 1,038 Cr | 28.05 | 2.96 | 0.06 | 10.54 | 16.04 | 7.98 | ||
514.70 | 1,031 Cr | 10.69 | 1.36 | 0.00 | 11.60 | 15.18 | 10.83 | ||
| Median: 7 Co. | — | 454.90 | 1,064 Cr | 28.05 | 2.96 | 0.06 | 10.54 | 10.75 | 4.44 |
